Our study also supports the notion that therapeutic strategies aiming to reinstate p53 function via inhibiting the protein–protein interaction between p53–MDM2 are less effective in the scenario that cancer cells have already adopted mechanisms beyond protein degradation to derail p53 signaling. Here, TP53 is linked to cancer.